ARK Investment Management LLC Has $579.16 Million Position in Tempus AI, Inc. $TEM

ARK Investment Management LLC reduced its stake in Tempus AI, Inc. (NASDAQ:TEM) by 3.3% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 7,175,767 shares of the company’s stock after selling 246,003 shares during the quarter. Tempus AI comprises 3.4% of ARK Investment Management LLC’s holdings, making the stock its 9th largest position. ARK Investment Management LLC owned 4.13% of Tempus AI worth $579,156,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds have also recently bought and sold shares of TEM. Renaissance Capital LLC increased its stake in shares of Tempus AI by 26.9% during the third quarter. Renaissance Capital LLC now owns 84,166 shares of the company’s stock worth $6,793,000 after purchasing an additional 17,866 shares during the period. Mirae Asset Global Investments Co. Ltd. grew its holdings in Tempus AI by 1,459.8% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 101,276 shares of the company’s stock valued at $8,174,000 after buying an additional 94,783 shares in the last quarter. Hussman Strategic Advisors Inc. bought a new position in Tempus AI during the 3rd quarter worth $1,695,000. Vanguard Group Inc. lifted its holdings in shares of Tempus AI by 22.1% during the third quarter. Vanguard Group Inc. now owns 9,441,607 shares of the company’s stock worth $762,032,000 after buying an additional 1,706,837 shares in the last quarter. Finally, Krane Funds Advisors LLC boosted its position in shares of Tempus AI by 218.2% in the third quarter. Krane Funds Advisors LLC now owns 28,230 shares of the company’s stock valued at $2,427,000 after acquiring an additional 19,358 shares during the period. 24.22% of the stock is currently owned by institutional investors and hedge funds.

Tempus AI Price Performance

Shares of TEM opened at $51.29 on Thursday. The company has a quick ratio of 3.00, a current ratio of 3.13 and a debt-to-equity ratio of 2.52. The stock has a market cap of $9.13 billion, a PE ratio of -36.38 and a beta of 5.29. Tempus AI, Inc. has a 12-month low of $36.22 and a 12-month high of $104.32. The business has a 50-day simple moving average of $60.57 and a two-hundred day simple moving average of $72.91.

Insider Activity

In other news, CEO Ryan Fukushima sold 9,592 shares of the business’s stock in a transaction that occurred on Thursday, February 19th. The shares were sold at an average price of $59.05, for a total value of $566,407.60. Following the transaction, the chief executive officer owned 694,354 shares in the company, valued at approximately $41,001,603.70. The trade was a 1.36% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Andrew Polovin sold 10,949 shares of the company’s stock in a transaction on Friday, February 20th. The shares were sold at an average price of $60.31, for a total transaction of $660,334.19. Following the sale, the executive vice president directly owned 126,918 shares in the company, valued at $7,654,424.58. This trade represents a 7.94% decrease in their position. The SEC filing for this sale provides additional information. In the last three months, insiders have sold 590,109 shares of company stock valued at $37,056,566. 26.27% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

Several brokerages have weighed in on TEM. Robert W. Baird started coverage on shares of Tempus AI in a research note on Tuesday, February 17th. They issued an “outperform” rating and a $59.00 price objective for the company. BTIG Research dropped their price target on shares of Tempus AI from $105.00 to $90.00 and set a “buy” rating for the company in a research report on Wednesday, February 25th. JPMorgan Chase & Co. reduced their price target on Tempus AI from $80.00 to $60.00 and set a “neutral” rating on the stock in a research report on Wednesday, February 25th. Stifel Nicolaus set a $60.00 price objective on Tempus AI in a report on Wednesday, February 25th. Finally, Wall Street Zen downgraded Tempus AI from a “hold” rating to a “sell” rating in a research report on Saturday, February 28th. Eight research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, Tempus AI presently has an average rating of “Moderate Buy” and a consensus price target of $78.15.

About Tempus AI

Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors.

The company’s core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data.